Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ResToP: Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response
2023-508993-27-00Phase 2Completed
- Sponsor
- CRIS Cancer Foundation
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in chronic myelogenous leukemia (CML), sponsored by CRIS Cancer Foundation. Primary endpoint: Proportion of patients with a maintained MMR within 52 weeks following ponatinib TFR. Started Dec 2023; status: completed.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2023-508993-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508993-27-00.